TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Estimates

TriSalus Life Sciences (NASDAQ:TLSI) released its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16), FiscalAI reports. The firm had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Q2 revenue reached $11.4 million, up sequentially and 1.7% year over year, while gross margin improved to 86.8% from 83.9% due to lower unit costs and manufacturing improvements.
• CMS issued a new G-code extending TriNav reimbursement into physician office-based labs, broadening access beyond hospitals and ambulatory surgery centers and potentially supporting adoption in liver, uterine, prostate, and genicular embolization.
• TriSalus has 11 active clinical studies across 27 sites involving more than 400 treated patients; additional trials are launching in the second half of 2026, while PETER data has been submitted for peer-reviewed publication and TriNav Advance remains under FDA review.
• Management reiterated 2026 revenue guidance of $54 million to $57 million, representing 19%–26% growth, and expects sequential growth acceleration in the second half as the expanded sales force becomes more productive and first-half expansion costs decline.
• The commercial build-out increased sales and marketing expenses to $11.4 million from $7.2 million, contributing to a wider adjusted EBITDA loss of $7.1 million versus $5.3 million a year earlier, although management said its $46.3 million cash balance funds the strategic plan.

TriSalus Life Sciences Stock Performance

Shares of TLSI opened at $5.61 on Friday. The business’s 50 day moving average price is $4.17 and its 200-day moving average price is $4.31. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The stock has a market cap of $344.57 million, a P/E ratio of -4.32 and a beta of 0.43.

Insiders Place Their Bets

In other news, Director Michael P. Stansky bought 200,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $2.50 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director owned 399,698 shares of the company’s stock, valued at $999,245. This trade represents a 100.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mary T. Szela bought 39,682 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the completion of the transaction, the chief executive officer directly owned 1,065,215 shares of the company’s stock, valued at $2,758,906.85. This represents a 3.87% increase in their position. The disclosure for this purchase is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have purchased a total of 719,682 shares of company stock worth $1,804,176 in the last 90 days. 16.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its holdings in shares of TriSalus Life Sciences by 1.5% during the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock worth $14,454,000 after acquiring an additional 30,582 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% in the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its holdings in shares of TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after purchasing an additional 265,618 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 35.5% in the fourth quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock valued at $5,245,000 after purchasing an additional 196,752 shares in the last quarter. Finally, State Street Corp increased its position in TriSalus Life Sciences by 37.4% in the fourth quarter. State Street Corp now owns 264,628 shares of the company’s stock worth $1,847,000 after purchasing an additional 71,995 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

TLSI has been the subject of a number of research reports. Weiss Ratings downgraded TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Lake Street Capital dropped their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.